

Nanomedicine Awards 2017

The European Technology Platform on Nanomedicine (ETPN) and ENATRANS announced the 2 recipients of the Nanomedicine Award 2017

Paris, November 8, 2017 – Patrick Boisseau the Chairman of the European Technology Platform on Nanomedicine officially announced yesterday the winners of the Nanomedicine Award 2017 at BIO-Europe conference in Berlin. The award review board agreed to distinguish two excellent projects: the Best Nanomedicine Early Clinical Stage Project the Best Nanomedicine Product/Deal.

Best Nanomedicine Early Clinical Stage Project Award

LIFNano Therapeutics (United Kingdom), with a project aiming to develop a nano-engineered healing factor (LIF) to treat multiple sclerosis: *“Cell free regenerative medicine. Nano-Engineered LIF to treat Multiple Sclerosis”* presented by Dr. Su Metfcalfe (<http://lifnano.com/>).

Best Nanomedicine Product-Deal Award

Aerogelex., (Germany) a start-up company incubated at Tutech Innovation GmbH with a project developing a new generation of nanoporous aerogels at a pilot scale: *“Biopolymer aerogels for Pharma, Nutrition, Life Sciences and Care”*, presented by Raman Subrahmanyam (<https://aerogelex.com/>).

“For this third edition of the Nanomedicine Award, we have received a great number of projects coming from all over the world, covering different healthcare areas, and I would like to point out the impressive high quality of the applications. It strongly illustrates the dynamism and the excellence of the research in the nanomedicine field. I wish great success to these two innovative projects, like former winners rewarded Nanomedicine Award in 2015, and the fastest way possible to help patients”, commented Patrick Boisseau, Chairman of the ETPN and member of the award review board.

=

ABOUT NANOMEDICINE AWARD - <http://nanomedicine-award.com>

Winners benefited from a full registration (including partnering) for BIO-Europe 2017 as well as a public presentation of their project during the BIO-Europe conference. In addition, the winners will be granted presentation slot during the ETPN Annual Event in May 2018 at Berlin, consulting action by the experts of the Translation Advisory Board (TAB) for experts' advice and high-level guidance and a 1 year's free ETPN membership.

The EBD group and Nanobiotix, are sponsors of this event which is co-organized by ETPN and ENATRANS

ABOUT ETPN - www.etp-nanomedicine.eu

Created in 2005, the European Technology Platform on Nanomedicine (ETPN), an initiative led by industry and set up together with the European Commission, is addressing the application of nanotechnology to achieve breakthroughs in healthcare. Its mission consists in building, shaping and supporting the European ecosystem of

Nanomedicine. ETPN has also developed solid and effective tools under the umbrella of the Nanomedicine Translation Hub aiming to select and help the development of the best innovative projects in Nanomedicine toward the clinic.

The Translation Hub notably includes the Nanomed Translation Advisory Board ([TAB](#)), the European Nanomedicine Characterization Lab ([EU-NCL](#)) and GMP Pilot lines.

Since 2015, the ETPN is an independent international Association under the French law 1901, with its Secretariat and headquarters located in Paris, France.

ABOUT ENATRANS - www.enatrans.eu

Enabling NANomedicineTRANslation, a Coordination and Support Action funded by the European Commission, has been built to help the translation of innovative projects related to Nanomedicine to successfully go through the different stages of development from the idea to the patients and also improve global knowledge on Nanomedicine. ENATRANS is led by a consortium of 7 partners belonging to the European Technology Platform for Nanomedicine (ETPN): CEA-LETI (Grenoble, France), Nanobiotix SA (Paris, France), Gesellschaft für Bioanalytik Muenster e.V. (Muenster, Germany), Tel-Aviv University (Tel-Aviv, Israel), Fondazione Don Carlo Gnocchi ONLUS (Milan, Italy), TecMinho (Braga, Portugal) and coordinated by VDI/VDE-IT (Berlin, Germany).

ABOUT BIO-EUROPE 2017 - www.ebdgroup.com/bioeurope

The 23rd annual BIO-Europe® event is the largest biotechnology partnering conference held in Europe. Over 3,200 international decision makers from biotech, pharma and finance along with the most promising start-ups and emerging companies, representing upwards of 1,800 companies, annually attend BIO-Europe to identify new business opportunities and develop strategic relationships. BIO-Europe features the industry's most advanced web-based partnering system enabling delegates from all parts of the biotechnology value chain to quickly identify, engage and enter into strategic relationships that drive their business successfully forward. BIO-Europe is taking place on November 6-8, 2017 in Berlin, Germany.

Follow BIO-Europe 2017 on Twitter: twitter.com/ebdgroup (hashtag: #BioEurope)

Nanobiotix - www.nanobiotix.com

Nanobiotix (Euronext: NANO / ISIN: FR0011341205) is a late clinical-stage nanomedicine company pioneering novel approaches for the treatment of cancer. The Company's first-in-class, proprietary technology, NanoXray, enhances radiotherapy energy with a view to providing a new, more efficient treatment for cancer patients. NanoXray products are compatible with current radiotherapy treatments and are meant to treat potentially a wide variety of solid tumors including soft tissue sarcoma, head and neck cancers, liver cancers, prostate cancer, breast cancer, glioblastoma, etc., via multiple routes of administration. NBTXR3 is being evaluated in: soft tissue sarcoma (STS), head and neck cancers, prostate cancer, and liver cancers (primary and metastases). Additionally, head and neck cancer and rectal cancer trials led by Nanobiotix's Taiwanese partner, PharmaEngine, are underway in the Asia Pacific region. The Company filed in August 2016 for market approval (CE Marking) in Europe for its lead product NBTXR3. In 2016 the Company started a new preclinical research program in Immunology with its lead product NBTXR3, which could have the potential to bring a new dimension to cancer immunotherapies.

Nanobiotix is listed on the regulated market of Euronext in Paris (ISIN: FR0011341205, Euronext ticker: NANO, Bloomberg: NANO: FP). The Company's Headquarters is based in Paris, France, with a U.S. affiliate in Cambridge, MA.

EBD Group - www.ebdgroup.com

EBD Group is the leading partnering firm for the global life science industry. Since 1993, biotech, pharma, medical device and related life science companies have leveraged EBD Group's partnering conferences, technology and services to identify business opportunities and develop strategic relationships essential to their success.

EBD Group's conferences, are run with the support of leading corporations and international trade associations, include BIO-Europe®, BIO-Europe Spring®, BioPharm America™, BioEquity Europe, ChinaBio® Partnering Forum, MedtechPartnering Forum and Biotech Showcase™.

EBD Group's sophisticated web-based partnering service, partneringONE®, is also used as the partnering engine at numerous third-party events around the world, and partnering360® is the open online community of life science dealmakers that enhances partnering experiences throughout the year.

EBD Group is an Informa company. Informa is the largest publicly-owned organizer of exhibitions, conferences and training in the world.

Contact

ETPN General Secretary

Alexandre CECCALDI
alexandre.ceccaldi@etp-nanomedicine.eu
tel: +33 6 13080780

ENATRANS Coordinator

Nicolas GOUZE
VDI/VDE-IT
nicolas.gouze@vdivde-it.de
Tel.: +49 30 310078 209

ENATRANS Communication

Sarah GAUBERT
Violaine EMOURGEON
sarah.gaubert@nanobiotix.com
violaine.emourgeon@nanobiotix.com
Tel.: + 33 1 75 44 69 42